These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 37796107)

  • 1. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
    Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
    Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.
    Labrecque MP; Coleman IM; Brown LG; True LD; Kollath L; Lakely B; Nguyen HM; Yang YC; da Costa RMG; Kaipainen A; Coleman R; Higano CS; Yu EY; Cheng HH; Mostaghel EA; Montgomery B; Schweizer MT; Hsieh AC; Lin DW; Corey E; Nelson PS; Morrissey C
    J Clin Invest; 2019 Jul; 129(10):4492-4505. PubMed ID: 31361600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.
    Corella AN; Cabiliza Ordonio MVA; Coleman I; Lucas JM; Kaipainen A; Nguyen HM; Sondheim D; Brown LG; True LD; Lee JK; MacPherson D; Nghiem P; Gulati R; Morrissey C; Corey E; Nelson PS
    Clin Cancer Res; 2020 Apr; 26(7):1667-1677. PubMed ID: 31806643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer.
    Turnham DJ; Mullen MS; Bullock NP; Gilroy KL; Richards AE; Patel R; Quintela M; Meniel VS; Seaton G; Kynaston H; Clarkson RWE; Phesse TJ; Nelson PS; Haffner MC; Staffurth JN; Pearson HB
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
    Labrecque MP; Brown LG; Coleman IM; Lakely B; Brady NJ; Lee JK; Nguyen HM; Li D; Hanratty B; Haffner MC; Rickman DS; True LD; Lin DW; Lam HM; Alumkal JJ; Corey E; Nelson PS; Morrissey C
    Cancer Res; 2021 Sep; 81(18):4736-4750. PubMed ID: 34312180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
    Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
    EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo.
    Zacharias N; Lee J; Ramachandran S; Shanmugavelandy S; McHenry J; Dutta P; Millward S; Gammon S; Efstathiou E; Troncoso P; Frigo DE; Piwnica-Worms D; Logothetis CJ; Maity SN; Titus MA; Bhattacharya P
    Mol Imaging Biol; 2019 Feb; 21(1):86-94. PubMed ID: 29748904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
    Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
    J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
    Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ
    Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.
    Qiao Y; Feng FY; Wang Y; Cao X; Han S; Wilder-Romans K; Navone NM; Logothetis C; Taichman RS; Keller ET; Palapattu GS; Alva AS; Smith DC; Tomlins SA; Chinnaiyan AM; Morgan TM
    Neoplasia; 2016 Jan; 18(1):1-9. PubMed ID: 26806347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A; Kim SH; Hwang C
    Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
    Zhang A; Lau NA; Wong A; Brown LG; Coleman IM; De Sarkar N; Li D; DeLucia DC; Labrecque MP; Nguyen HM; Conner JL; Dumpit RF; True LD; Lin DW; Corey E; Alumkal JJ; Nelson PS; Morrissey C; Lee JK
    Cancer Res Commun; 2023 Nov; 3(11):2358-2374. PubMed ID: 37823778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
    Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
    Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
    Gowda PS; Deng JD; Mishra S; Bandyopadhyay A; Liang S; Lin S; Mahalingam D; Sun LZ
    Mol Cancer Res; 2013 Nov; 11(11):1448-61. PubMed ID: 23989930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.